Study on the effect and mechanism of metoprolol and flunarizine

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006120

Enrollment

Unknown

Registered

2015-02-16

Start date

2015-04-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

A:Metoprolol Tartrate tablet 50mg/d

B:Flunarizine Hydrochloride capsule 5mg/d

C:Metoprolol Tartrate tablet 50mg/d combined Flunarizine Hydrochloride capsule 5mg/d

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of migraine with and without aura was established according to the criteria of ICHD-3 beta; 2. lasted more than 1 year; 3. >3 migraine attacks per month before inclusion; 4. onset age <50; 5. age 18-65 years at enrollment; 6. prophylactic drugs was stopped for at least 1 month; 7. to be able to keep the headache diary.

Exclusion criteria

Exclusion criteria: 1. Pregnant women and nursing mothers; 2. Kidney disease, liver disease and malignant tumor; 3. allergic to Metoprolol or Flunarizine.

Design outcomes

Primary

Measure	Time frame
frequency (attacks per month);intensity;duration;serum CGRP level;	—

Contacts

Public ContactWu Tao

wu835148631@163.com+86 18813188154

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026